Literature DB >> 7517175

CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

N A Breslin1, R L Suddath, G Bissette, C B Nemeroff, P Lowrimore, D R Weinberger.   

Abstract

Neurotensin (NT), a peptide which colocalizes with dopamine in some midbrain and hypothalamic neurons, has been speculated to play a role in schizophrenic illness and in the action of antipsychotic drugs. Previous work suggested a bimodal distribution of NT in patients with schizophrenia, with a subgroup having low drug-free NT concentrations which normalize with neuroleptic treatment. We studied 15 schizophrenic patients with CSF samples collected both off and on neuroleptic medication, 12 with only drug-free (DF) samples, and 10 controls. There was no significant difference in CSF NT concentrations between patients and controls, or between patients off and on medication. However, 7 patients with DFNT CSF concentrations below the patient mean showed an increase with neuroleptic treatment. Moreover, NT was significantly lower for women. Significant correlations with NT concentrations in CSF were found with deficit symptoms in patients, and with the age of the CSF sample for all subjects. There was no correlation between CSF NT concentrations and patient age, duration of illness, or levels of amine metabolites (MHPG, 5HIAA, HVA).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517175     DOI: 10.1016/0920-9964(94)90082-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.

Authors:  E B Binder; B Kinkead; M J Owens; C D Kilts; C B Nemeroff
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

4.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

6.  Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.

Authors:  J M Radke; M J Owens; J C Ritchie; C B Nemeroff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

7.  Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Andres Gordillo; Shuhua Li; Elliott Richelson
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

8.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

9.  The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Joanna Peris; Elliott Richelson
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.